A study was designed to confirm this hypothesis in which 10 patients with multiple myeloma and prior stem cell transplant with a duration of response < 1 year who required a salvage stem cell transplant were also infused with anti-CD19 CAR T-cell therapy using CTL019 (Garfall et al., 2015). Here, CD19 is linked to plasma cell myeloma.